ClinicalTrials.gg
RecruitingNCT07181434REVDOUUpdated Aug 31, 2026

Impact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation

An interventional study of The patient will be equipped with VR headsets in Peripheral Arterial Disease, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.

Planned enrollment
37th of 66
90 · median 106
Started
2026
with 1 other
No phase
43 of 120
11 open now
Primary completion
2027-09
later than 18 of 26 live
Registered
115th of 120
by date

Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 37th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 43 with no phase, reaches primary completion later than 18 of the 26 other live ones, and was the 115th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Peripheral Arterial Disease with a site in France, or all of them as a file.
02

Study summary

The prevalence of peripheral arterial disease (PAD) increases with age In addition to medical treatment, endovascular procedures can be performed, depending on the stage of the disease, to prevent complications and/or sequelae (relapse, functional loss of the affected limb, amputation, death), but also to relieve pain. This is a minimally invasive procedure most often performed under local anesthesia (LA), sometimes with the administration of sedatives (morphine and analgesics) to relieve pain and reduce anxiety related to the procedure.

Non-pharmacological methods such as virtual reality (VR) are increasingly being used as an alternative to general anesthesia and excessive opioid use.

The hypothesis is that VR could reduce pain during lower limb revascularization by endovascular surgery.

Read the detailed description

The prevalence of peripheral arterial disease (PAD) increases with age. In high-income countries, it is 5% between the ages of 45 and 49, and 18% after the age of 85. In France, nearly 1 million people are affected by this disease.

In addition to medical treatment, endovascular procedures can be performed, depending on the stage of the disease, to prevent complications and/or sequelae (relapse, functional loss of the affected limb, amputation, death), but also to relieve pain. This is a minimally invasive procedure most often performed under local anesthesia (LA), sometimes with the administration of sedatives (morphine and analgesics) to relieve pain and reduce anxiety related to the procedure.

Local anesthesia causes discomfort related to the operating environment (low temperature, harsh lighting, noise, supine position, arms along the body, cold, hard, narrow table), impacting patient cooperation and making the procedure difficult, with the need to take multiple X-rays and reinject potentially nephrotoxic contrast agents. It can lead to the procedure being stopped, with serious consequences (postponement, persistent or even worsening pain, amputation, death).

Non-pharmacological methods such as virtual reality (VR) are increasingly being used as an alternative to general anesthesia and excessive opioid use.

It has proven effective in managing pain and anxiety during various medical, surgical, and endovascular procedures. Its high-quality graphics immerse the patient; hypnotic speech and relaxing elements capture the patient's attention; breathing exercises help manage stress; and relaxing music creates a soothing atmosphere. This support ensures greater mental and physical comfort by reducing pain and anxiety.

The hypothesis is that VR could reduce pain during lower limb revascularization by endovascular surgery.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Virtual reality
  • pain management
  • virtual reality headset
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient suffering from PAD, scheduled to undergo endovascular surgery for lower limb revascularization under local anesthesia combined with sedation.
  • Age ≥ 18 years.
  • Patient who understands and speaks French.
  • Patient covered by social security or covered through a third party.
  • Free subject, without guardianship, curatorship, or subordination.
  • Patient who has given their free and .

Exclusion criteria

Exclusion Criteria:

  • Patients with to VR headsets (mono- or binocular blindness, epilepsy, migraines, psychiatric disorders, pacemakers, hearing aids, defibrillators, recent injuries to the eyes, face, or scalp that prevent comfortable use of the headsets, etc.).
  • Patients with suspected intolerance to VR headsets (sensitivity to motion sickness in cars, history of balance or eye disorders, etc.);
  • Previous bad experience with VR headsets;
  • Patients undergoing local regional anesthesia (LRA);
  • Persons requiring enhanced protection, namely persons deprived of their liberty by judicial or administrative decision, pregnant women, and finally patients in life-threatening situations.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    In addition to the usual care, the patient will be equipped with VR headsets

    In addition to the usual care, the patient will be equipped with VR headsets showing one of the six scenes from the HealthyMind® program in 3D, accompanied by hypnotic speech during the procedure.

    Device: The patient will be equipped with VR headsets

  • No intervention
    The patient will receive the usual treatment under local anesthesia

    The patient will receive standard care under local anesthesia with an analgesic injection (paracetamol) +/- morphine sedation (remifentanil), according to the treatment protocol and tailored to the patient.

Interventions

  • DeviceThe patient will be equipped with VR headsets

    The patient will be equipped with VR headsets showing one of the six scenes from the HealthyMind® program in 3D, accompanied by hypnotic speech during the procedure.

06

What researchers measure

Primary outcomes

  1. The maximum level of pain experienced by the patient during the procedure

    The maximum level of pain will be assessed at the the end of the procedure using a numerical rating scale ranging from 0 (no pain) to 10 (worst pain imaginable)

    Time frame: At the end of the revascularization procedure

Secondary outcomes

  1. The difference in anxiety measures assessed at baseline and just after the intervention

    Anxiety will be measured at baseline and just after the intervention using a numerical rating scale ranging from 0 for "no anxiety" to 10 for "maximum imagined anxiety": a quick, easy-to-use scale that correlates strongly with Spielberger's STAI scale (Benotsch et al., 2000).

    Time frame: At Baseline and just after the intervention of lower limb revascularization through endovascular surgery

  2. Systolic Blood Pressure (SBP) in mmHg

    Time frame: At Baseline before the procedure of lower limb revascularization through endovascular surgery, upon arrival in the operating room, then every 15 minutes until the end of the procedure.

  3. Diastolic Blood Pressure (DBP) in mmHg

    Time frame: At Baseline before the procedure of lower limb revascularization through endovascular surgery, upon arrival in the operating room, then every 15 minutes until the end of the procedure.

  4. Heart Rate (HR) in cycles/min

    Time frame: At Baseline before the procedure of lower limb revascularization through endovascular surgery, upon arrival in the operating room, then every 15 minutes until the end of the procedure.

  5. Respiratory Rate (RR) in Breaths Per Minute (BPM)

    Time frame: At Baseline before the procedure of lower limb revascularization through endovascular surgery, upon arrival in the operating room, then every 15 minutes until the end of the procedure.

  6. Cumulated doses of analgesics consumed during the procedure (in mL/kg)

    Cumulated doses will be standardized in mL/kg in order to obtain comparable measures accros patients

    Time frame: During the revascularization procedure

  7. The dose of X-ray radiation

    Total dose of X-ray radiation absorbed by the patient (dose-area product, in mGy.cm²)

    Time frame: During the procedure of revascularization of the lower limbs by endovascular surgery

  8. The total volume of contrast medium delivered during the procedure

    Time frame: During the procedure of revascularization of the lower limbs by endovascular surgery

  9. The difference between the duration of the procedure as perceived by the patient and the actual duration of the procedure (in minutes)

    Time frame: At the end of the procedure of revascularization of the lower limbs by endovascular surgery

  10. The success rate of the procedure

    Proportion of procedures performed successfully (total revascularization of the artery)

    Time frame: At the end of the procedure of revascularization of the lower limbs by endovascular surgery

  11. Proportion of patients who kept the virtual reality headsets on throughout the procedure

    Outcome assessed for the experimental group only (with VR headset)

    Time frame: Throughout the procedure of lower limb revascularization through endovascular surgery

  12. Satisfaction level of the virtual reality headset

    Satisfaction will be measured with a numerical rating scale ranging from 0 (not satisfied at all) to 10 (completely satisfied). Outcome assessed for the experimental group only (with VR headset)

    Time frame: At the end of the procedure of lower limb revascularization through endovascular surgery

  13. Comfort level experienced by the patient during the procedure

    Comfort will be measured after the procedure using a numerical rating scale ranging from 0 (very uncomfortable) to 10 (very comfortable).

    Time frame: Comfort will be assessed at the end of the revascularization procedure

  14. Cumulated doses of morphine derivatives consumed during the procedure (in mL/kg)

    Cumulated doses will be standardized in mL/kg in order to obtain comparable measures accross patients

    Time frame: During the revascularization procedure

  15. Cumulated doses of anesthetics consumed during the procedure (in mL/kg)

    Cumulated doses will be standardized in mL/kg in order to obtain comparable measures accross patients

    Time frame: During the revascularization procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 18 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Sep 18, 2025
StartActual
Mar 3, 2026
Primary completionEst.
Sep 3, 2027
CompletionEst.
Sep 3, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181434
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Mar 3, 2026
Primary completion
Sep 3, 2027 (estimated)
Completion
Sep 3, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Amélie PETIT
Contact
Amelie.PETIT@chu-poitiers.fr
+33 5 49 44 69 70

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion